MAIA Biotechnology CEO buys 10,500 shares at $0.97 in Form 4/A

MAIA Biotechnology, Inc. Chief Executive Officer and director Vlad Vitoc, a more than 10% owner of the company, reported an open-market purchase of common stock.

Rhea-AI Filing Summary

MAIA Biotechnology, Inc. Chief Executive Officer and director Vlad Vitoc, a more than 10% owner of the company, reported an open-market purchase of common stock. On 11/25/2025, he bought 10,500 shares of MAIA common stock at a price of $0.9661 per share. Following this transaction, he directly owned 831,421 common shares and indirectly held 210,100 common shares through his spouse.

This filing is an amendment to a prior Form 4 originally filed on 11/28/2025. The amendment corrects the previously reported total share balance owned by Mr. Vitoc’s spouse and now reflects the correct indirect ownership amount, while also reiterating that he disclaims beneficial ownership of those spouse-held shares except to the extent of his economic interest.

Insider Trade Summary

Net Buyer: 10,500 shares

Net Buy 2 txns

Insider Vitoc Vlad

Role Chief Executive Officer

Bought 10,500 shs ($10K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	10,500	$0.9661	$10K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 831,421 shares (Direct); Common Stock — 210,100 shares (Indirect, See Footnote)

Footnotes (2)

1. F1. The original Form 4 filed November 28, 2025 had the incorrect total share balance owned by Mr. Vitoc's spouse. This Amended Form 4 is now reflecting the correct share balance owned.
2. F2. These securities are beneficially owned by Mr. Vitoc's spouse. The reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did MAIA (MAIA) report for Vlad Vitoc?

Vlad Vitoc reported purchasing 10,500 shares of MAIA Biotechnology, Inc. common stock on 11/25/2025 at a price of $0.9661 per share.

How many MAIA Biotechnology (MAIA) shares does Vlad Vitoc own after this transaction?

After the reported transaction, Vlad Vitoc directly owned 831,421 shares of MAIA common stock and indirectly held 210,100 shares through his spouse.

Why was this MAIA (MAIA) Form 4/A filed as an amendment?

The amendment was filed because the original Form 4 submitted on 11/28/2025 reported an incorrect total share balance owned by Mr. Vitoc’s spouse. This Form 4/A corrects that spouse share balance.

What is the relationship of Vlad Vitoc to MAIA Biotechnology, Inc. (MAIA)?

Vlad Vitoc is a director, a more than 10% owner, and serves as the Chief Executive Officer of MAIA Biotechnology, Inc.

How are the spouse’s MAIA (MAIA) shares treated in this insider report?

The 210,100 shares are reported as indirectly owned by Vlad Vitoc through his spouse, and he disclaims beneficial ownership of those shares except to the extent of his pecuniary interest.

Does this MAIA Biotechnology (MAIA) filing involve any derivative securities?

The provided tables include a section for derivative securities, but no specific derivative transactions or holdings are reported in the excerpt.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 12/04/2025 - 07:31 AM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Vitoc Vlad

(Last) (First) (Middle)

444 WEST LAKE STREET,

(Street)

CHICAGO IL 60606

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
MAIA Biotechnology, Inc. [ MAIA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
11/25/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)
11/28/2025

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/25/2025		P		10,500	A	$0.9661	831,421	D
Common Stock								210,100(1)	I	See Footnote(2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The original Form 4 filed November 28, 2025 had the incorrect total share balance owned by Mr. Vitoc's spouse. This Amended Form 4 is now reflecting the correct share balance owned.

2. These securities are beneficially owned by Mr. Vitoc's spouse. The reporting person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.

	/s/ Vlad Vitoc	12/03/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.